A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab

被引:16
|
作者
Miyoshi, Fumihiko [1 ,5 ]
Honne, Kyoko [2 ]
Minota, Seiji [2 ]
Okada, Masato [3 ]
Ogawa, Noriyoshi [4 ]
Mimura, Toshihide [1 ]
机构
[1] Saitama Med Univ, Dept Rheumatol & Appl Immunol, Fac Med, Morohongo 38, Moroyama, Saitama 3500495, Japan
[2] Jichi Med Univ, Div Rheumatol & Clin Immunol, Shimotsuke, Tochigi, Japan
[3] St Lukes Int Hosp, Immunorheumatol Ctr, Tokyo, Japan
[4] Hamamatsu Univ Sch Med, Internal Med 3, Div Rheumatol & Immunol, Hamamatsu, Shizuoka, Japan
[5] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Biol Res Labs, Saitama, Japan
关键词
Clinical data; Infliximab; Machine-learning; Rheumatoid arthritis; The prediction of clinical response; MONOCLONAL-ANTIBODY; EXPRESSION PROFILE; BLOOD-CELLS; RESPONSIVENESS; THERAPIES; CANCER;
D O I
10.3109/14397595.2016.1168536
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to generate a novel method for predicting the clinical response to infliximab (IFX), using a machine-learning algorithm with only clinical data obtained before the treatment in rheumatoid arthritis (RA) patients. Methods: We obtained 32 variables out of the clinical data on the patients from two independent hospitals. Next, we selected both clinical parameters and machine-learning algorithms and decided the candidates of prediction method. These candidates were verified by clinical variables on different patients from two other hospitals. Finally, we decided the prediction method to achieve the highest score. Results: The combination of multilayer perceptron algorithm (neural network) and nine clinical parameters shows the best accuracy performance. This method could predict the good or moderate response to IFX with 92% accuracy. The sensitivity of this method was 96.7%, while the specificity was 75%. Conclusions: We have developed a novel method for predicting the clinical response using only background clinical data in RA patients before treatment with IFX. Our method for predicting the response to IFX in RA patients may have advantages over the other previous methods in several points including easy usability, cost-effectiveness and accuracy.
引用
收藏
页码:813 / 816
页数:4
相关论文
共 50 条
  • [1] A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab
    Miyoshi, Fumihiko
    Honne, Kyoko
    Minota, Seiji
    Okada, Masato
    Ogawa, Noriyoshi
    Mimura, Toshihide
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S627 - S628
  • [2] Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis
    Stone, M
    Salonen, D
    Lax, M
    Payne, U
    Lapp, V
    Inman, R
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (07) : 1605 - 1614
  • [3] Good clinical response to infliximab and methotrexate in new RA-patients parallels a decrease in synovial inflammation
    Van Oosterhout, M
    Allaart, CF
    Levarht, EWN
    Toes, REM
    Breedveld, FC
    Van Laar, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 188 - 188
  • [4] Infliximab provides additional clinical and radiographic benefits in RA patients who have an inadequate response to etanercept
    Furst, D
    Yocum, D
    Weisman, M
    Troum, O
    Bray, V
    Wallace, D
    Gaylis, N
    Ritter, J
    Yeilding, N
    Gilmer, K
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 427 - 427
  • [5] Good clinical response to infliximab and methotrexate in new RA-patients parallels a decrease in synovial inflammation.
    van Oosterhout, M
    Allaart, CF
    Levarht, EWN
    Toes, REM
    Breedveld, FC
    Van Laar, JM
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S134 - S134
  • [6] Predicting treatment response to methotrexate in atopic dermatitis patients using clinical characteristics and serum biomarkers
    Ariens, L.
    Thijs, J.
    Bakker, D.
    Drylewicz, J.
    Nierkens, S.
    Knol, E.
    Delemarre, E.
    Balak, D.
    van der Schaft, J.
    de Bruin-Weller, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S287 - S287
  • [7] Leveraging Machine Learning Approaches for Predicting Antidepressant Treatment Response Using Electroencephalography (EEG) and Clinical Data
    Jaworska, Natalia
    de la Salle, Sara
    Ibrahim, Mohamed-Hamza
    Blier, Pierre
    Knott, Verner
    FRONTIERS IN PSYCHIATRY, 2019, 9
  • [8] Cost Per Clinical Remission and Clinical Response of Adalimumab, Golimumab, and Infliximab in the Treatment of Patients with Ulcerative Colitis: An Induction Analysis
    Mallow, Peter
    Rizzo, John
    Queener, MaryKay
    Gathany, Timothy
    Lofland, Jennifer
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S515 - S516
  • [9] USING CLINICAL ROUTINE DATA TO PREDICT PRIMARY RESPONSE TO INFLIXIMAB THERAPIES IN CROHN'S DISEASE
    Ye, Xiaoqi
    Zhang, Sheng-Hong
    Cai, Jing
    Yu, Qiao
    Cao, Xiaocang
    Cao, Qian
    Chen, Minhu
    GASTROENTEROLOGY, 2020, 158 (06) : S955 - S955
  • [10] FOUR YEAR OUTCOME DATA IN RHEUMATOID ARTHRITIS (RA) PATIENTS RECEIVING EITHER ETANERCEPT OR INFLIXIMAB IN STANDARD CLINICAL PRACTICE
    Greenwood, Mandy C.
    Donnelly, Simon P.
    Rooney, Margaretta M.
    Hakim, Alan J.
    Tahir, Hasan
    RHEUMATOLOGY, 2009, 48 : I64 - I64